Coherus Oncology Prices $50M Public Stock Offering

Got story updates? Submit your updates here. ›

Coherus Oncology, Inc., a commercial-stage oncology company, announced the pricing of an underwritten public offering of 28.6 million shares of its common stock at $1.75 per share. The gross proceeds from the offering are expected to be approximately $50.1 million, which the company plans to use to support the ongoing commercialization of its cancer drug LOQTORZI, continue clinical development of its pipeline, and for general corporate purposes.

Why it matters

The public stock offering will provide Coherus Oncology with additional capital to advance its oncology portfolio, including the commercialization of its approved PD-1 inhibitor LOQTORZI and the development of its pipeline candidates targeting various solid tumor types. This financing comes as the company looks to grow sales of LOQTORZI and expand its clinical programs.

The details

The underwritten public offering consists of 28.6 million shares of Coherus Oncology's common stock sold at $1.75 per share. The company has also granted the underwriters a 30-day option to purchase up to an additional 4.29 million shares. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners for the offering, which is expected to close on or about February 17, 2026.

• The public offering was priced on February 12, 2026.
• The offering is expected to close on or about February 17, 2026.

What’s next

The offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.